-
Uncategorized1 month ago
Amgen, Sanofi commit nearly $600M to North American expansions
Sanofi’s investment will support a Canadian site’s efforts to apply AI to drug production, while Amgen has unveiled the second expansion of its Puerto Rico plant...
-
Uncategorized1 month ago
Novo hikes guidance on Wegovy pill’s fast sales start
In its latest earnings report, the Danish drugmaker said sales and profit should shrink less than the company originally anticipated thanks to strong prescription numbers for...
-
Uncategorized1 month ago
CoCoGraph AI Model Generates Molecules that Comply with Rules of Chemistry
Developing new molecular compounds is crucial to address pressing challenges, from drug discovery to sustainable materials. However, discovering viable new molecules is challenging due to the...
-
Uncategorized1 month ago
Madrigal’s Rezdiffra beats estimates; Gilead cuts jobs; Banyan debuts
🚀 Madrigal Pharmaceuticals’ MASH drug beats expectations: The biotech’s Rezdiffra sales came in at $311 million for the first quarter, surpassing analysts’ projections by about $10...
-
Uncategorized1 month ago
Ipsen scuttles liver disease candidates from $952M Albireo acquisition
Ipsen has set aside the two drug candidates it picked up from a 2023 acquisition of liver disease specialist Albireo, with one of the assets discontinued...
-
Uncategorized1 month ago
Unforced errors flummox HHS’ radical transparency bid—again
Robert F. Kennedy Jr.’s health department has consistently touted radical transparency as being key to its mission. Recent instances—the FDA’s decision not to disclose the recipients...
-
Uncategorized1 month agoAvalo shares spike on skin drug data; BioNTech to cut staff
Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an...
-
Uncategorized1 month agoLab automation strong despite global challenges
The world of drug discovery definitely kept us on our toes last year. Uncertainty in the market, not helped by the challenges created by changes in...
-
Uncategorized1 month ago
Novo’s Wegovy pill reaches 1M patients, shattering expectations with $355M in sales
Analysts and investors alike had been eagerly awaiting sales figures for Novo Nordisk’s Wegovy pill. The answer blew past expectations by 86%.
-
Uncategorized1 month ago
GSK goes to China for $1B siRNA deal in Arrowhead’s obesity lane
GSK is further delving into the cardiometabolic space — and deepening its relationship with China biotechs — in a $1 billion biobucks deal with an siRNA...
